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Background: The TAXUS Liberte Post-Approval Study (TL-PAS) is a prospective,
multicenter US registry which enrolled 4199 patients, of which 1592 were deﬁned as
“on-label”, i.e. treated as per the FDA-approved labeling for TL. Unique features of
this registry include the TL stent and exclusive use of at least 12 months of prasugrel
as part of a dual antiplatelet therapy (DAPT) strategy after stenting. Previous work
demonstrated that in-hospital major adverse cardiac events (MACE) were favorable
when compared to the TAXUS Express ARRIVE registries, which utilized the
TAXUS Express (TE) stent and clopidogrel.
Methods: Patients were enrolled at 82 sites between December 2009 - January 2012.
After stenting, patients were prescribed aspirin and prasugrel (5 mg or 10 mg doses, as
appropriate) for 12 months. Statistical testing was performed to determine if the
primary endpoint of 12-month cardiac death or MI for the TL stent was non-inferior to
the TE stent. A total of 2463 “on-label” patients receiving the TL stent from the
TL-PAS (n¼1592) and TAXUS ATLAS Workhorse studies (WH; n¼871) were
compared to the 3676 "on-label" TE-treated patients in the control arm of TAXUS
ATLAS WH (n¼978) and ARRIVE 1/2 registries (n¼2698). Secondary outcomes
including MACE (death, MI or target vessel failure), stent thrombosis and GUSTO
moderate/severe bleeding are reported in the overall and "on-label" populations of
TL-PAS.
Results: Rates of the primary endpoint of cardiac death and MI were 3.0% (108/3554)
with TE and 2.2% (52/2384) with TL; thus the criteria for non-inferiority were met
(p<0.0001). Low rates of other adverse cardiac outcomes and bleeding were observed
(Table) and were lower in the on-label group.Control TAXUS Liberté
Variable (N=3676)b (N=2463)c
Primary Endpoint: Cardiac
Death or MIa
3.0% (108/3554) 2.2% (52/2384)
TAXUS Liberte PAS TAXUS Liberte PAS
Overall On-label
(N¼4199 Patients)d (N¼1592 Patients)e
MACE 7.2% (295) 4.8% (74)
TVF 6.3% (259) 4.6% (71)
Death 1.3% (55) 0.6% (9)
Cardiac Death 0.9% (37) 0.2% (3)
Cardiac Death or MI 2.1% (87) 0.9% (14)
MI 1.4% (57) 0.7% (11)
TVR 5.8% (236) 4.2% (65)
Stent Thrombosis (Protocol) 0.9% (36) 0.3% (4)
Major Bleeding (GUSTO
moderate/severe)
3.6% (146) 3.0% (47)
A: Non-inferiority comparison p<0.0001; binary rates; B: on label TE-treated patients from the
control arm of the TAXUS ATLAS Workhorse Clinical Trial and the ARRIVE 1 and 2 registries; C:
on-label TL-treated patients in the TAXUS ATLAS Workhorse Clinical Trial and TL-PAS; D: all
patients enrolled in TL-PAS; KM estimates; E: on-label patients
B54 JACC Vol 62/18/Suppl B j October 27–November 1, 2013Conclusions: The 1 year TL-PAS primary endpoint results show low rates of cardiac
death/ MI (as well as overall MACE, stent thrombosis, and bleeding) utilizing
a strategy of TAXUS Liberté stent and DAPT including prasugrel.
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Background: Drug eluting stent (DES) has been vastly used for percutaneous coro-
nary intervention (PCI), but its late restenosis has been reported and long term beneﬁt
has been questionable especially in large size stent.
Methods: Consecutive 12276 patients who received PCI between 2004 and 2011
were included in the study. Patients were divided into 4 groups: small bare metal stent
(BMS), large BMS, small DES and large DES group depending on kind and size of
implanted stents. Small stent was deﬁned as its size was 3.25mm or smaller. Large
stent was deﬁned as the others. Selection of each stent was decided by operators.
Average observation period was 1488 days. Shortest and longest observation periods
were 1 and 2647 days. All-cause mortality and target lesion revascularization (TLR)
rate was compared. Hazard ratio (HR) of morality and TLR in small DES and large
BMS compared to small BMS, and in large DES compared to large BMS and its 95%
conﬁdence intervals (CIs) were calculated with multivariate Cox regression analysis
adjusted for patient background.
Results: 522, 2096, 3328 and 394 patients were included in small BMS, small
DES, large BMS and large DES group. Mortality was observed in each group was
475 (7.3%), 128 (6.1%), 202 (6.1%) and 23 (5.8%) patients. TLR was observed in
332 (5.1%), 112 (5.3%), 134 (4.0%) and 32 (8.1%) patients. HRs of mortality
compared to small BMS in small DES, large BMS and large DES were 0.99 (95%
CI: 0.80-1.22, p ¼ 0.92), 0.84 (95% CI: 0.70-1.01, p ¼ 0.068) and 0.80 (95% CI:
0.48-1.33, p ¼ 0.39). HR of mortality in large DES compared to large BMS was
1.01 (95% CI: 0.60-1.72, p ¼ 0.97). HRs of TLR compared to small BMS in small
DES, large BMS and large DES were 1.04 (95% CI: 0.83-1.29, p ¼ 0.75), 0.72
(95% CI: 0.59-0.88, p ¼ 0.002), and 1.40 (95% CI: 0.97-2.03, p ¼ 0.070). HR of
TLR compared to large BMS in large DES was 1.83 (95% CI: 1.24-2.70,
p ¼ 0.002).
Conclusions: No signiﬁcant difference was observed in mortality. Large BMS
signiﬁcantly reduced TLR compared to small BMS. Large DES signiﬁcantly increased
TLR compared to large BMS. Large BMS showed lowest TLR rate among all groups
tested.
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Background: The aim of this registry is to evaluate the clinical performance of
a new generation Sirolimus eluting stent system (Osiro) in a large patient pop-
ulation in standard clinical care. The Osiro is a unique hybrid solution that
combines passive and active components. PROBIO passive coating encapsulates
the stent and minimizes interaction between the metal stent and surrounding tissue.
BIOlute active coating contains a highly biocompatible and biodegradable
polymer.
Methods: Between August 2011 and March 2012, 1,356 subjects were enrolled
consecutively in this international, multicentric BIOFLOW-III all-comers registry
using the Osiro Sirolimus eluting stent. Primary endpoint is Target Lesion Failure
(TLF) at twelve months follow-up. Pre-speciﬁed subgroups were diabetes, small
vessels, chronic total occlusion and acute myocardial infarction.
Results: Nine hundred seventy one men (72%) and three hundred eighty ﬁve
women were enrolled at 43 sites in 14 countries. The mean age was 66.1  10.7,
ranging from 29-91 years. Based on our preliminary data, the majority of subjects
presented with hypertension 76%, hypercholesteremia 60%, smoker 55%, and
diabetes 30% 48% of all stented vessels had a diameter 2.75mm, 4% presented
with chronic total occlusion. Eleven percent of the subjects experienced unstable
angina, 47% stable angina. Acute MI was seen in 33% of the subjects (NSTEMI
22%, STEMI 11%). The portion of elderly subjects ( 75 years) is represented by
25%. Ninety seven percent (1,321) follow up compliance at six months and ninety
ﬁve percent (1,289) at twelve months were achieved. An unbiased patient pop-
ulation was seen in the registry with more than 52% type B2/C lesions. Moderate
and severe calciﬁcation was observed in 31%. The Osiro hybrid stent system
demonstrated excellent device (98.7%) and procedure success (98.2%). In thisj TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
